Program Schedule — Atlantic Standard Time (UTC-4)
12:15 PM – 12:45 PM — Registration and Lunch Buffet
12:45 PM – 2:15 PM — Educational Meeting
Location
Puerto Rico Convention Center
100 Convention Boulevard
San Juan, Puerto Rico
Phone: +1 (787) 641-7722
Meeting Room
Room 209 (Level 2)
No registration fee is charged for this event. For the in-person symposium in San Juan, preregistration is required as seating is limited.
Faculty Floor J Backes, MD
Professor
Larry J Copeland Professorship in Gynecologic Oncology
Director of Clinical Research
Associate Fellowship Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio
Matthew A Powell, MD
Ira C and Judith Gall Professor
Division of Gynecologic Oncology
Chair, Uterine Corpus Committee
National Cancer Institute-Sponsored NRG Oncology
Washington University School of Medicine
St Louis, Missouri
Moderator Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California
This activity is supported by an educational grant from GSK.
Program Schedule — Atlantic Standard Time (UTC-4)
12:15 PM – 12:45 PM — Registration and Lunch Buffet
12:45 PM – 2:15 PM — Educational Meeting
MODULE 1: Biology of Advanced Endometrial Cancer; Optimal Approach to Biomarker Assessment for Patients with Newly Diagnosed Disease
Clinical characteristics associated with various histologic subtypes of endometrial cancer; relationship between histologic subtype and response to available therapies
Rationale for the division of endometrial cancer into major molecular subgroups; implications of each of these for prognosis and therapeutic decision-making
Indications for and optimal approach to assessment for biomarkers of response to immune checkpoint inhibition (eg, microsatellite instability [MSI]/mismatch repair [MMR] status, POLE mutations, tumor mutational burden, PD-L1 status) in patients with advanced endometrial cancer
Incidence and prognostic or predictive implications of BRCA1/2 and other homologous recombination repair (HRR) gene mutations in patients with advanced endometrial cancer; current and future role of HRR testing
Guideline-endorsed approach to assessment for other clinically relevant biomarkers (eg, TP53 status, HER2 and hormone receptor status) in advanced endometrial cancer
MODULE 2: Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer
Similarities and differences among the designs of and populations enrolled in the Phase III RUBY, NRG-GY018 and DUO-E trials evaluating the addition of dostarlimab, pembrolizumab and durvalumab, respectively, to platinum-based chemotherapy as first-line treatment for advanced or recurrent endometrial cancer
Published progression-free survival, overall survival and other efficacy and safety outcomes from RUBY, NRG-GY018 and DUO-E
Antitumor activity observed with chemotherapy in combination with dostarlimab, pembrolizumab and durvalumab, respectively, in various patient subgroups (based on MSI/MMR status, HER2 status, molecular subtype, etc) in RUBY, NRG-GY018 and DUO-E
FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent endometrial cancer regardless of MMR status and of durvalumab in combination with chemotherapy for those with MMR-deficient disease; optimal incorporation into up-front therapy
Ongoing Phase III studies (eg, DOMENICA, KEYNOTE-C93) evaluating first-line anti-PD-1/PD-L1 inhibitor monotherapy for MSI-high/MMR-deficient advanced or recurrent endometrial cancer
MODULE 3: Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced Endometrial Cancer
Rationale for the evaluation of PARP inhibition for advanced endometrial cancer; possible therapeutic synergy between anti-PD-1/PD-L1 antibodies and PARP inhibitors
Key efficacy and safety findings from the Phase III RUBY Part 2 and DUO-E trials evaluating first-line chemoimmunotherapy followed by anti-PD-1/PD-L1 antibody and PARP inhibitor maintenance for newly diagnosed advanced or recurrent endometrial cancer; outcomes in various patient subsets
Potential patient selection for and roles of anti-PD-1/PD-L1 antibody and PARP inhibitor maintenance for advanced endometrial cancer
Long-term findings with pembrolizumab/lenvatinib for advanced endometrial cancer previously treated with a platinum-based regimen; optimal integration into current management algorithms
Published findings supporting the utility of bevacizumab for TP53-mutant advanced endometrial cancer; ongoing Phase III NRG-GY035 study evaluating the addition of bevacizumab to up-front chemoimmunotherapy for MMR-proficient, TP53-mutated disease
Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.
Learning Objectives
Upon completion of this activity, participants should be able to
Assess the clinical and biological characteristics of the various histologic subtypes and molecular subgroups of endometrial cancer and consider the implications for prognosis and therapeutic decision-making.
Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment in the management of endometrial cancer, and adapt current testing practices to optimally identify patients with corresponding genetic abnormalities.
Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer, and educate patients with MSI-high/MMR-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
Understand the biological rationale for and available data with the use of PARP inhibitors in combination with immune checkpoint inhibitor therapy for advanced or metastatic endometrial cancer.
Recognize available data with the use of anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic endometrial cancer for this novel approach.
Recognize adverse events associated with immune checkpoint inhibitor-based approaches used in the treatment of endometrial cancer to educate patients and manage complications.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.
FACULTY
— The following faculty reported relevant financial relationships with ineligible entities:
Dr Backes — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BioNTech SE, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, ImmunoGen Inc, Merck; Contracted Research: AbbVie Inc, ImmunoGen Inc, Merck, Natera Inc; Data and Safety Monitoring Boards/Committees: MacroGenics Inc.
Dr Powell — Consulting Agreements: Eisai Inc, GSK, Merck; Contracted Research: GSK.
MODERATOR Dr Salani — Advisory Committees: AbbVie Inc, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, Merck, Pfizer Inc, Whitehawk Therapeutics; Nonrelevant Financial Relationships: UpToDate.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by an educational grant from GSK.
Puerto Rico Convention Center
100 Convention Boulevard
San Juan, Puerto Rico 00907
Phone: +1 (787) 641-7722
Meeting Room
Room 209 (Level 2)
Directions
The Puerto Rico Convention Center is the main venue for the 2026 SGO Annual Meeting on Women’s Cancer.
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.
No registration fee is charged for this event. At this time in-person registration for this educational activity is limited to practicing clinicians actively caring for patients with cancer. For all other professionals, including industry personnel,* we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information by choosing the second registration option below. Should seats become available for the program, we will notify you.
NOTICE Registration for this event is independent of registration for the 2026 SGO Annual Meeting on Women’s Cancer.
IN-PERSON registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
STANDBY IN-PERSON registration for other/industry professionals*
If you would like to stand by for participation in this event, please provide your contact information here. We will notify you if seats become available. You are welcome to attend virtually — please register below with the WEBCAST option.
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
